Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT

User menu

Search

  • Advanced search
eNeuro
eNeuro

Advanced Search

 

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT
PreviousNext
Research ArticleNew Research, Sensory and Motor Systems

Effects of Fluoxetine and Visual Experience on Glutamatergic and GABAergic Synaptic Proteins in Adult Rat Visual Cortex

Simon Beshara, Brett R. Beston, Joshua G. A. Pinto and Kathryn M. Murphy
eNeuro 24 December 2015, 2 (6) ENEURO.0126-15.2015; https://doi.org/10.1523/ENEURO.0126-15.2015
Simon Beshara
1McMaster Integrative Neuroscience Discovery and Study (MiNDS) Program, McMaster University, Hamilton, Ontario L8S 4K1, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brett R. Beston
1McMaster Integrative Neuroscience Discovery and Study (MiNDS) Program, McMaster University, Hamilton, Ontario L8S 4K1, Canada
2Department of Psychology, Neuroscience & Behavior, McMaster University, Hamilton, Ontario L8S 4K1, Canada
3Department of Psychology, University of Toronto Mississauga, Mississauga, L5L 1C6, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua G. A. Pinto
1McMaster Integrative Neuroscience Discovery and Study (MiNDS) Program, McMaster University, Hamilton, Ontario L8S 4K1, Canada
4Health Care Investment Banking, Credit Suisse AG, San Francisco, CA 94108
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathryn M. Murphy
1McMaster Integrative Neuroscience Discovery and Study (MiNDS) Program, McMaster University, Hamilton, Ontario L8S 4K1, Canada
2Department of Psychology, Neuroscience & Behavior, McMaster University, Hamilton, Ontario L8S 4K1, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig 1.

    Presynaptic and postsynaptic proteins in ipsilateral V1. In V1 ipsilateral to the deprived eye, there was no effect of experimental condition on the expression of synapsin (A), synaptophysin (B), PSD-95 (C), or gephyrin (D). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

  • Fig 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig 2.

    Presynaptic vesicle cycling and transporter proteins. In contralateral V1, synapsin (A) was not affected by experimental condition. For synaptophysin (B) fluoxetine alone had no effect, MD alone caused a loss of expression, but combining fluoxetine with MD prevented the MD-induced loss. For VGLUT1 (C) fluoxetine alone or with MD caused a loss of expression, but MD alone increased expression. VGAT (D) was not affected by experimental condition. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

  • Fig 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig 3.

    Postsynaptic receptor scaffolding proteins and subunits. In contralateral V1, PSD-95 (A) and gephyrin (B) had a similar pattern of changes: fluoxetine alone had no effect, MD alone caused a loss of expression, but combining fluoxetine with MD prevented the MD-induced loss and caused super-compensation above normal levels. GluN1 (C) was reduced by fluoxetine regardless of visual experience, whereas MD alone caused an increase. GluA2 (D) was unaffected by fluoxetine alone, MD caused an increase, but combing fluoxetine with MD caused a decrease. GluN2B (E) was reduced by fluoxetine regardless of visual experience, whereas MD had no effect. GluN2A (F) expression of each experimental group was not different from normal animals, but the MDed group had higher expression than either fluoxetine alone or fluoxetine combined with MD. GABAAα3 (G) was unaffected by fluoxetine alone, MD caused an increase, but combing fluoxetine with MD prevented the MD-induced increase. GABAAα1 (H) was increased by fluoxetine regardless of visual experience, while MD alone had no effect. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

  • Fig 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig 4.

    Postsynaptic receptor subunit balances. Neither fluoxetine, MD, nor fluoxetine combined with MD affected the relative abundance of GluN1-containing NMDARs and GluA2-containing AMPARs in contralateral V1 (A). Fluoxetine shifted the relative abundance of NMDAR subunits in favor of the more mature GluN2A subunit, regardless of visual experience. MD caused a shift in favor of the more immature GluN2B (B). Fluoxetine shifted the relative abundance of GABAAR subunits in favor of the more mature α1 subunit, regardless of visual experience. MD caused a shift in favor of the more α3 subunit (C). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

  • Fig 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig 5.

    Presynaptic and Postsynaptic E/I balance. Presynaptic Index in contralateral V1 (A): (VGLUT1−VGAT)/(VGLUT1+VGAT). Postsynaptic Index in contralateral V1 (B): (PSD-95−gephyrin)/(PSD-95+gephyrin). We found strikingly similar patters in the presynaptic and postsynaptic indexes of E/I synapses. Fluoxetine caused a slight shift toward inhibition in the presynaptic index and had no effect on the postsynaptic index. MD caused a strong shift to excitatory markers. Combining fluoxetine and MD kept the balance at normal levels. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Tables

  • Figures
    • View popup
    Table 1.

    Statistical table

    Data pointData structureType of test95% Confidence interval vs normal95% Confidence interval vs fluoxetine95% Confidence interval vs 1 week MD95% Confidence interval vs fluoxetine + 1 week MD
    V1 Ipsi synapsin - NormalNormalBootstrapping + Monte Carlo Simulation0.8112–1.18880.7825–1.23801.1441–0.82790.7813–0.9824
    V1 Ipsi synapsin- fluoxetineNormalBootstrapping + Monte Carlo Simulation0.8388–1.16120.8131–1.20741.1275–0.84450.7945–0.9692
    V1 Ipsi synapsin - 1 week MDNormalBootstrapping + Monte Carlo Simulation0.8094–1.19060.7820–1.23841.1457–0.82630.7798–0.9839
    V1 Ipsi synapsin - fluoxetine + 1 week MDNormalBootstrapping + Monte Carlo Simulation0.8378–1.16220.8126–1.20791.1258–0.84620.7951–0.9686
    V1 Ipsi synaptophysin - NormalNormalBootstrapping + Monte Carlo Simulation0.8812–1.11880.8583–1.17570.9164–1.23470.9007–1.1095
    V1 Ipsi synaptophysin - fluoxetineNormalBootstrapping + Monte Carlo Simulation0.8957–1.10430.8817–1.15230.9400–1.21100.9152–1.0950
    V1 Ipsi synaptophysin - 1 week MDNormalBootstrapping + Monte Carlo Simulation0.8783–1.12170.8604–1.17350.9147–1.23640.9011–1.1091
    V1 Ipsi synaptophysin - fluoxetine + 1 week MDNormalBootstrapping + Monte Carlo Simulation0.8977–1.10230.8782–1.15580.9352–1.21590.9150–1.0953
    V1 Ipsi PSD-95 – NormalNormalBootstrapping + Monte Carlo Simulation0.6143–1.38570.7437–1.22621.0125–1.30420.9502–1.3776
    V1 Ipsi PSD-95 - fluoxetineNormalBootstrapping + Monte Carlo Simulation0.6678–1.33220.7799–1.19001.0345–1.28230.9780–1.3498
    V1 Ipsi PSD-95 - 1 week MDNormalBootstrapping + Monte Carlo Simulation0.6117–1.38830.7469–1.22301.0125–1.30430.9499–1.3779
    V1 Ipsi PSD-95 - fluoxetine + 1 week MDNormalBootstrapping + Monte Carlo Simulation0.6678–1.33220.7799–1.19001.0325–1.28430.9765–1.3513
    V1 Ipsi gephyrin - NormalNormalBootstrapping + Monte Carlo Simulation0.7124–1.28760.7326–1.25700.9003–1.14180.9795–1.2321
    V1 Ipsi gephyrin - fluoxetineNormalBootstrapping + Monte Carlo Simulation0.7491–1.25090.7669–1.22280.9169–1.12530.9974–1.2142
    V1 Ipsi gephyrin - 1 week MDNormalBootstrapping + Monte Carlo Simulation0.7048–1.29520.7297–1.25990.9035–1.13860.9795–1.2320
    V1 Ipsi gephyrin - fluoxetine + 1 week MDNormalBootstrapping + Monte Carlo Simulation0.7533–1.24670.7677–1.22190.9182–1.12390.9961–1.2155
    V1 contra synapsin- normalNormalBootstrapping + Monte Carlo Simulation0.8105–1.18950.7781–1.24240.5763–1.13350.7372–1.3212
    V1 contra synapsin- fluoxetineNormalBootstrapping + Monte Carlo Simulation0.8384–1.16160.8055–1.21500.6118–1.09790.7764–1.2820
    V1 contra synapsin - 1 week MDNormalBootstrapping + Monte Carlo Simulation0.8138–1.18620.7726–1.24780.5732–1.13650.7322–1.3262
    V1 contra synapsin - fluoxetine + 1 week MDNormalBootstrapping + Monte Carlo Simulation0.8381–1.16190.8103–1.21020.6112–1.09860.7680–1.2904
    V1 contra synaptophysin - normalNormalBootstrapping + Monte Carlo Simulation0.8801–1.11990.8473–1.15550.7132–1.02310.8204–1.0900
    V1 contra synaptophysin - fluoxetineNormalBootstrapping + Monte Carlo Simulation0.8777–1.12230.8663–1.13660.7315–1.00480.8387–1.0717
    V1 contra synaptophysin - 1 week MDNormalBootstrapping + Monte Carlo Simulation0.8959–1.10410.8459–1.15690.7144–1.02190.8202–1.0902
    V1 contra synaptophysin - fluoxetine + 1 week MDNormalBootstrapping + Monte Carlo Simulation0.8930–1.10700.8693–1.13360.7350–1.00130.8389–1.0715
    V1 contra VGLUT1 - normalNormalBootstrapping + Monte Carlo Simulation0.8693–1.13070.6128–0.80791.0116–1.48280.7065–1.0228
    V1 contra VGLUT1 - fluoxetineNormalBootstrapping + Monte Carlo Simulation0.8872–1.11280.6250–0.79571.0435–1.45090.7247–1.0046
    V1 contra VGLUT1 - 1 week MDNormalBootstrapping + Monte Carlo Simulation0.8685–1.13150.6107–0.81001.0034–1.49100.7044–1.0249
    V1 contra VGLUT1 - fluoxetine + 1 week MDNormalBootstrapping + Monte Carlo Simulation0.8876–1.11240.6227–0.79801.0387–1.45570.7228–1.0065
    V1 contra VGAT - normalNormalBootstrapping + Monte Carlo Simulation0.6458–1.35420.5777–1.25800.6151–1.02780.6073–1.3463
    V1 contra VGAT - fluoxetineNormalBootstrapping + Monte Carlo Simulation0.6993–1.30070.6330–1.20270.6390–1.00390.6511–1.3025
    V1 contra VGAT - 1 week MDNormalBootstrapping + Monte Carlo Simulation0.6512–1.34880.5808–1.25490.6160–1.02690.6015–1.3521
    V1 contra VGAT - fluoxetine + 1 week MDNormalBootstrapping + Monte Carlo Simulation0.6956–1.30440.6339–1.20190.6414–1.00150.6515–1.3020
    V1 contra PSD-95 - normalNormalBootstrapping + Monte Carlo Simulation0.6038–1.39620.7218–1.18610.4462–0.81740.9084–2.0180
    V1 contra PSD-95 - fluoxetineNormalBootstrapping + Monte Carlo Simulation0.6683–1.33170.7503–1.15750.4720–0.79160.9719–1.9545
    V1 contra PSD-95 - 1 week MDNormalBootstrapping + Monte Carlo Simulation0.6097–1.39030.7204–1.18750.4505–0.81310.9037–2.0227
    V1 contra PSD-95 - fluoxetine + 1 week MDNormalBootstrapping + Monte Carlo Simulation0.6679–1.33210.7493–1.15850.4700–0.79370.9767–1.9497
    V1 contra gephyrin - NormalNormalBootstrapping + Monte Carlo Simulation0.7050–1.29500.7343–1.34320.4036–0.70360.8690–1.8151
    V1 contra gephyrin - fluoxetineNormalBootstrapping + Monte Carlo Simulation0.7480–1.25200.7847–1.29280.4257–0.68150.9298–1.7543
    V1 contra gephyrin - 1 week MDNormalBootstrapping + Monte Carlo Simulation0.7089–1.29110.7444–1.33310.4053–0.70190.8845–1.7996
    V1 contra gephyrin - fluoxetine + 1 week MDNormalBootstrapping + Monte Carlo Simulation0.7515–1.24850.7858–1.29160.4304–0.67680.9435–1.7406
    V1 contra GluN1 - normalNormalBootstrapping + Monte Carlo Simulation0.8909–1.10920.6978–1.00431.0128–1.48520.6713–0.9632
    V1 contra GluN1 - fluoxetineNormalBootstrapping + Monte Carlo Simulation0.9037–1.09630.7187–0.98341.0445–1.45360.6910–0.9434
    V1 contra GluN1 - 1 week MDNormalBootstrapping + Monte Carlo Simulation0.8910–1.10900.6980–1.00421.0159–1.48220.6696–0.9648
    V1 contra GluN1 - fluoxetine + 1 week MDNormalBootstrapping + Monte Carlo Simulation0.9053–1.09470.7206–0.98151.0457–1.45230.6897–0.9447
    V1 contra GluA2 - normalNormalBootstrapping + Monte Carlo Simulation0.8632–1.13680.7766–1.02051.0076–1.34600.7128–0.9906
    V1 contra GluA2 - fluoxetineNormalBootstrapping + Monte Carlo Simulation0.8824–1.11760.7943–1.00281.0326–1.32100.7128–0.9906
    V1 contra GluA2 - 1 week MDNormalBootstrapping + Monte Carlo Simulation0.8605–1.13950.7774–1.01971.0017–1.35190.7368–0.9667
    V1 contra GluA2 - fluoxetine + 1 week MDNormalBootstrapping + Monte Carlo Simulation0.8790–1.12100.7940–1.00301.0316–1.32200.7310–0.9724
    V1 contra GluN2A - normalNormalBootstrapping + Monte Carlo Simulation0.7104–1.28960.6612–1.04710.9664–1.50400.7161–1.1003
    V1 contra GluN2A - fluoxetineNormalBootstrapping + Monte Carlo Simulation0.7063–1.29370.6880–1.02031.0035–1.46690.7431–1.0733
    V1 contra GluN2A - 1 week MDNormalBootstrapping + Monte Carlo Simulation0.7430–1.25690.6628–1.04550.9607–1.50970.7190–1.0974
    V1 contra GluN2A - fluoxetine + 1 week MDNormalBootstrapping + Monte Carlo Simulation0.7418–1.25820.6832–1.02511.0056–1.46480.7427–1.0737
    V1 contra GluN2B - normalNormalBootstrapping + Monte Carlo Simulation0.7772–1.22280.5712–0.86360.8007–1.15220.6562–0.9201
    V1 contra GluN2B - fluoxetineNormalBootstrapping + Monte Carlo Simulation0.7812–1.21880.5881–0.84660.8229–1.13000.6740–0.9022
    V1 contra GluN2B - 1 week MDNormalBootstrapping + Monte Carlo Simulation0.8074–1.19260.5659–0.86880.8029–1.15000.6584–0.9179
    V1 contra GluN2B - fluoxetine + 1 week MDNormalBootstrapping + Monte Carlo Simulation0.8120–1.18800.5862–0.84850.8239–1.12890.6728–0.9034
    V1 contra GABAA3 - normalNormalBootstrapping + Monte Carlo Simulation0.8712–1.12880.7659–1.05770.9939–1.37210.7512–1.0196
    V1 contra GABAA3 - fluoxetineNormalBootstrapping + Monte Carlo Simulation0.8908–1.10920.7856–1.03801.0139–1.35200.7645–1.0063
    V1 contra GABAA3 - 1 week MDNormalBootstrapping + Monte Carlo Simulation0.8729–1.12710.7641–1.05960.9921–1.37380.7447–1.0261
    V1 contra GABAA3 - fluoxetine + 1 week MDNormalBootstrapping + Monte Carlo Simulation0.8894–1.11060.7883–1.03531.0207–1.34520.7655–1.0053
    V1 contra GABAA1 - normalNormalBootstrapping + Monte Carlo Simulation0.8751–1.12490.8854–1.58930.7594–1.27980.5585–1.9208
    V1 contra GABAA1 - fluoxetineNormalBootstrapping + Monte Carlo Simulation0.8898–1.11020.9302–1.54450.7971–1.24220.6434–1.8359
    V1 contra GABAA1 - 1 week MDNormalBootstrapping + Monte Carlo Simulation0.8713–1.12870.8863–1.58830.7642–1.27510.5339–1.9454
    V1 contra GABAA1 - fluoxetine + 1 week MDNormalBootstrapping + Monte Carlo Simulation0.8883–1.11170.9312–1.54350.7932–1.24610.6465–1.8328
    V1 contra GluA2–GluN1 - normalNormalBootstrapping + Monte Carlo Simulation–0.0675 to 0.0603–0.0351 to 0.0859–0.0838 to 0.0295–0.0379 to 0.0676
    V1 contra GluA2–GluN1 – fluoxetineNormalBootstrapping + Monte Carlo Simulation–0.0595 to 0.0523–0.0279 to 0.0787–0.0766 to 0.0223–0.0304 to 0.0601
    V1 contra GluA2–GluN1 - 1 week MDNormalBootstrapping + Monte Carlo Simulation–0.0675 to 0.0603–0.0360 to 0.0868–0.0834 to 0.0291–0.0370 to 0.0667
    V1 contra GluA2–GluN1 - fluoxetine + 1 week MDNormalBootstrapping + Monte Carlo Simulation–0.0596 to 0.0525–0.0270 to 0.0778–0.0774 to 0.0231–0.0317 to 0.0614
    V1 contra GluN2A–GluN2B – NormalNormalBootstrapping + Monte Carlo Simulation–0.1879 to 0.0107–0.0659 to 0.0841–0.0451 to 0.1269–0.0775 to 0.0616
    V1 contra GluN2A–GluN2B – fluoxetineNormalBootstrapping + Monte Carlo Simulation–0.1755 to –0.0018–0.0553 to 0.0735–0.0331–0.1149–0.0694 to 0.0536
    V1 contra GluN2A–GluN2B - 1 week MDNormalBootstrapping + Monte Carlo Simulation–0.1862 to 0.0090–0.0679 to 0.0862–0.0456 to 0.1274–0.0767 to 0.0608
    V1 contra GluN2A–GluN2B - fluoxetine + 1 week MDNormalBootstrapping + Monte Carlo Simulation–0.1738 to –0.0034–0.0569 to 0.0752–0.0347 to 0.1165–0.0684 to 0.0526
    V1 contra GABAA1–GABAA3 - NormalNormalBootstrapping + Monte Carlo Simulation–0.1582 to 0.0079–0.0817 to 0.1848–0.2900 to –0.0325–0.1058 to 0.1577
    V1 contra GABAA1:GABAA3 - fluoxetineNormalBootstrapping + Monte Carlo Simulation–0.1463 to –0.0039–0.0619 to 0.1650–0.2744 to –0.0481–0.0873 to 0.1392
    V1 contra GABAA1:GABAA3 - 1 week MDNormalBootstrapping + Monte Carlo Simulation–0.1594 to 0.0092–0.0804 to 0.1835–0.2919 to –0.0306–0.1062 to 0.1582
    V1 contra GABAA1:GABAA3 - fluoxetine + 1 week MDNormalBootstrapping + Monte Carlo Simulation–0.1472 to –0.0031–0.0610 to 0.1641–0.2729 to –0.0496–0.0866 to 0.1385
    V1 contra Presynaptic E/I - NormalNormalBootstrapping + Monte Carlo Simulation–0.0981 to 0.1807–0.2242 to 0.07310.0853–0.3517–0.1710 to 0.1301
    V1 contra Presynaptic E/I - fluoxetineNormalBootstrapping + Monte Carlo Simulation–0.0809 to 0.1635–0.2033 to 0.05230.1032–0.3338–0.1525 to 0.1116
    V1 contra Presynaptic E/I - 1 week MDNormalBootstrapping + Monte Carlo Simulation–0.0983 to 0.1808–0.2288 to 0.07770.0850–0.3520–0.1725 to 0.1316
    V1 contra Presynaptic E/I - fluoxetine + 1 week MDNormalBootstrapping + Monte Carlo Simulation–0.0770 to 0.1595–0.2074 to 0.05630.0987–0.3383–0.1521 to 0.1112
    V1 contra Postsynaptic E/I - NormalNormalBootstrapping + Monte Carlo Simulation–0.1202 to 0.1499–0.1150 to 0.07450.0653–0.3197–0.0334 to 0.1542
    V1 contra Postsynaptic E/I - fluoxetineNormalBootstrapping + Monte Carlo Simulation–0.0999 to 0.1295–0.1009 to 0.06040.0834–0.3016–0.0208 to 0.1417
    V1 contra Postsynaptic E/I - 1 week MDNormalBootstrapping + Monte Carlo Simulation–0.1199 to 0.1495–0.1155 to 0.07500.0629–0.3221–0.0324 to 0.1532
    V1 contra Postsynaptic E/I - fluoxetine + 1 week MDNormalBootstrapping + Monte Carlo Simulation–0.1008 to 0.1304–0.1021 to 0.06160.0818–0.3032–0.0210 to 0.1418
Back to top

In this issue

eneuro: 2 (6)
eNeuro
Vol. 2, Issue 6
November/December 2015
  • Table of Contents
  • Index by author
Email

Thank you for sharing this eNeuro article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Effects of Fluoxetine and Visual Experience on Glutamatergic and GABAergic Synaptic Proteins in Adult Rat Visual Cortex
(Your Name) has forwarded a page to you from eNeuro
(Your Name) thought you would be interested in this article in eNeuro.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
Effects of Fluoxetine and Visual Experience on Glutamatergic and GABAergic Synaptic Proteins in Adult Rat Visual Cortex
Simon Beshara, Brett R. Beston, Joshua G. A. Pinto, Kathryn M. Murphy
eNeuro 24 December 2015, 2 (6) ENEURO.0126-15.2015; DOI: 10.1523/ENEURO.0126-15.2015

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Effects of Fluoxetine and Visual Experience on Glutamatergic and GABAergic Synaptic Proteins in Adult Rat Visual Cortex
Simon Beshara, Brett R. Beston, Joshua G. A. Pinto, Kathryn M. Murphy
eNeuro 24 December 2015, 2 (6) ENEURO.0126-15.2015; DOI: 10.1523/ENEURO.0126-15.2015
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Significance Statement
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
    • Synthesis
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Keywords

  • adult plasticity
  • amblyopia
  • fluoxetine
  • monocular deprivation
  • receptors
  • visual cortex

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

New Research

  • A Very Fast Time Scale of Human Motor Adaptation: Within Movement Adjustments of Internal Representations during Reaching
  • TrkB Signaling Influences Gene Expression in Cortistatin-Expressing Interneurons
  • Optogenetic Activation of β-Endorphin Terminals in the Medial Preoptic Nucleus Regulates Female Sexual Receptivity
Show more New Research

Sensory and Motor Systems

  • Robust representation and nonlinear spectral integration of harmonic stacks in layer 4 of mouse primary auditory cortex
  • Changes in Palatability Processing across the Estrous Cycle Are Modulated by Hypothalamic Estradiol Signaling
  • Automatic, but not autonomous: Implicit adaptation is modulated by goal-directed attentional demands
Show more Sensory and Motor Systems

Subjects

  • Sensory and Motor Systems
  • Home
  • Alerts
  • Follow SFN on BlueSky
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Latest Articles
  • Issue Archive
  • Blog
  • Browse by Topic

Information

  • For Authors
  • For the Media

About

  • About the Journal
  • Editorial Board
  • Privacy Notice
  • Contact
  • Feedback
(eNeuro logo)
(SfN logo)

Copyright © 2026 by the Society for Neuroscience.
eNeuro eISSN: 2373-2822

The ideas and opinions expressed in eNeuro do not necessarily reflect those of SfN or the eNeuro Editorial Board. Publication of an advertisement or other product mention in eNeuro should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in eNeuro.